Коморбидность сердечно-сосудистых и онкологических заболеваний: проблемы диагностики кардиотоксических эффектов химио- и лучевой терапии


Цитировать

Полный текст

Аннотация

Сердечно-сосудистые заболевания (ССЗ) и онкологические заболевания (ОЗ) занимают лидирующие позиции по распространенности и причинам смерти в экономически развитых странах, что определяет их высокую медико-социальную значимость для общества. Совершенствование методов ранней диагностики и лечения ОЗ способствовало увеличению безрецидивной выживаемости и продолжительности жизни этих больных. Вместе с тем появились новые проблемы, в частности развитие различных сердечно-сосудистых осложнений/заболеваний при лечении ОЗ, которые могут ухудшать прогноз у больного и быть самостоятельной причиной смерти. Поиск новых маркеров кардиотоксичности на ранних стадиях, разработка эффективных методов профилактики и персонифицированного лечения больного с ОЗ и ССЗ — проблемы, которые могут быть решены только совместными усилиями кардиологов и онкологов.

Об авторах

И Е Чазова

Российский кардиологический научно-производственный комплекс» Минздрава России

Москва

Е В Ощепкова

Российский кардиологический научно-производственный комплекс» Минздрава России

Москва

А Ю Канторова

Российский кардиологический научно-производственный комплекс» Минздрава России

Москва

Список литературы

  1. Информационный бюллетень №297 СМИ ВОЗ Февраль 2012 г. Russian (Informacionnyj bjulleten’ N297 SMI VOZ Fevral’ 2012 g.).
  2. Hong RA, Limura T, Sumida KN, Eager RM. Cardio-Oncology/Onco-Cardiology. Clin Cardiol. 2010;33:733-737.
  3. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-2247.
  4. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879.
  5. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20: 1215-1221.
  6. Giordano SH, Booser DJ, Murray JL et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three- hour- infusion paclitaxel in patients with metastatic breast cancer. Clin CancerRes. 2002;8:3360-3368.
  7. van Dalen EC, Caron HN, Dickinson HO et al. Cardioprotective interventions for cancer patients receiving anthracyclines.Cochrane Database Syst Rev 2005; CD003917. http://www.cochrane.org. Accessed April 16, 2008.
  8. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127-145.
  9. van Dalen EC, van der Pal HJH, Bakker PJM et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer. 2004;40:643-652.
  10. Guglin M, Hartlage G, Reynolds C et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009;15:651-657.
  11. Ewer MS, Vooletich MT, Durand J et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820-7826.
  12. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679-686.
  13. Atallah E, Durand J, Kantarjian H et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233-1237.
  14. Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500-2508.
  15. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370: 2011-2019.
  16. Kantarjian H, Cortes J, Kim D et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113: 6322-6329.
  17. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758-763.
  18. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 1991;99:557-561.
  19. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
  20. Van Cutsem E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13:484-485.
  21. Ang C, Kornbluth M, Thirlwell MP et al. Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol. 2010;17:59-63.
  22. Tsibiribi P, Descotes J, Lombard-Bohas C et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. BullCancer. 2006;93:E27-E30.
  23. Schwarzer S, Eber B, Greinix H et al. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991;12:748-750.
  24. Yano S, Shimada K. Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J. 1996;60:185-188.
  25. Swerdlow AJ, Higgins CD, Smith P et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206-214.
  26. Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep. 1986;70: 690-691.
  27. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99: 1232-1239.
  28. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
  29. Arbuck SG, Strauss H, Rowinsky E et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;15:117-130.
  30. Lee RE, Lotze MT, Skibber JM et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989;7:7-20.
  31. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:852-3860.
  32. McLellan RA, Drobitch RK, Monshouwer M et al. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos. 1996;24:1134-1138.
  33. Fang J, Gorrod JW. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol. 1999;19:491-510.
  34. Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res. 1995;19:141-144.
  35. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-423.
  36. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
  37. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25: 3109-3115.
  38. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session, 2003.
  39. Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol and cardiovascular disease. Hypertension. 2000;36:912-916.
  40. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. AnnIntern Med. 2003;139:761-776.
  41. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3d ed. Dallas, TX: Lippincott Williams & Wilkins. 2003:516-519.
  42. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27:766-773.
  43. Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150: 977-982.
  44. Gyenes G, Fornander T, Carlens P et al. Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. Eur JNucl Med. 1997;24:286-292.
  45. Cuzick J, Stewart H, Rutqvist L et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447-453.
  46. Hooning MJ, Botma A, Aleman BMP et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365-375.
  47. Dolci A, Dominici R, Cardinale D et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130(5):688-695.
  48. Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J AmColl Cardiol. 2000;36(2):517-522.
  49. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-2754.
  50. Cаржевский В.О., Колесникова Д.С., Мельниченко В.Я., Тюрин В.П. Кардиотоксичность высокодозной химиотерапии и аутологичной трансплантации костного мозга при онкогематологических заболеваниях. Клиническая онкогематология. 2013;6(3):324-332.
  51. Auner HW, Tinchon C, Linkesch W et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003;82(4):218-222.
  52. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-2481.
  53. Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136(2):362-363.
  54. Nousiainen T, Jantunen E, Vanninen E et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol. 1998;61(5):347-353.
  55. Horacek JM, Pudil R, Tichy M et al. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp Oncol. 2007;29(3):243-247.
  56. Snowden JA, Hill GR, Hunt P et al. Assessment of cardiotoxicity during hematopoietic cell transplantation with plasma brain natriuretic peptide. Bone MarrowTransplant. 2000;26(3):309-313.
  57. Zver S, Zadnik V, Bunc M et al. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007;85(5):408-414.
  58. Munker R, Lazarus HM, Atkinson K. The BMT Data Book. 2nd ed. Cambridge: Cambridge University Press; 2009:237.
  59. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5(2):91-98.
  60. Styler MJ, Topolsky DL, Crilley PA et al. Transient high grade heart block following autologous bone marrow infusion. Bone Marrow Transplant. 1992;10(5):435-438.
  61. Chung T, Lim WC, Sy R et al. Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart. 2008;94(7):911-918.
  62. Pihkala J, Saarinen UM, Lundstrom U et al. Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant. 1994;13(2):149-155.
  63. Zver S, Zadnik V, Cernelc P et al. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int JHematol. 2008;88(2):227-236.
  64. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). M.; 2010:428.
  65. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592-1600.
  66. Ganz WI, Sridhar KS, Ganz SS et al. Review of tests for mon- itoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461-470.
  67. van Dalen EC, van den Brug M, Caron HN et al. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer. 2006;42:3199-3205.
  68. Steinherz LJ, Graham T, Hurwitz R et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89(5 pt 1):942-949.
  69. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24: 4107-4115.
  70. Nousiainen T, Vanninen E, Jantunen E et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251:228-234.
  71. Donmez A, Zoghi M, Cagirgan S et al. The effect of hematopoietic progenitor cells’ temperature on cardiac arrhythmias in patients given peripheral blood progenitor cells. Transfus Apher Sci. 2006;34(3):245-251.
  72. Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492-2498.
  73. Silber JH, Cnaan A, Clark BJ et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22(5):820-828.
  74. Lipshultz SE, Lipsitz SR, Sallan SE et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20(23):4517-4522.
  75. Kakavas PW, Ghalie R, Parrillo JE et al. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant. 1995;15(6):859-861.
  76. Bosch X, Esteve J, Sitges M et al. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail. 2011;17(8):643-648.
  77. De Angelis A, Piegari E, Cappetta D et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276-292.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2015

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59